INC Research has acquired Trident Clinical Research, expanding its clinical outsourcing capabilities in Australia, New Zealand and India. Trident will become a wholly owned affiliate of INC Research and will operate as Trident Clinical Research through its offices in Sydney, Brisbane, Melbourne, Adelaide, Auckland and Mumbai.

Trident is one of Australia’s largest CROs, with more than 100 employees across three countries, a full range of clinical research services and diverse therapeutic experience.

“Trident is an important piece in our strategy to build a sustainable CRO business that both satisfies and anticipates the global drug development needs of our customers,” said James Ogle, chief executive officer of INC Research. “Trident has established an exceptional reputation in the region with emerging biotechs to local affiliates of global pharmaceutical companies and major principal investigator units. We are very happy to add them to our team.”

“The R&D opportunities in Australia, New Zealand and India for cost-effective local and global drug development programs are enormous,” said Garth Tierney, managing director and co-founder of Trident Clinical Research, who will assume the role of regional general manager, Australasia at INC Research. “We bring to bear the most experienced management team and staff in the region, which underscores INC Research’s on-the-ground capabilities. We look forward to leveraging INC Research’s Resources and Trusted Process methodology to enhance our services.”